Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

BACKGROUND: Prostate cancer (PCa) has been under investigation as a target for antigen-specific immunotherapies in metastatic disease settings for the last two decades leading to a licensure of the first therapeutic cancer vaccine, Sipuleucel-T, in 2010. However, neither Sipuleucel-T nor other exper...

Descripción completa

Detalles Bibliográficos
Autores principales: Cappuccini, Federica, Bryant, Richard, Pollock, Emily, Carter, Lucy, Verrill, Clare, Hollidge, Julianne, Poulton, Ian, Baker, Megan, Mitton, Celia, Baines, Andrea, Meier, Armin, Schmidt, Guenter, Harrop, Richard, Protheroe, Andrew, MacPherson, Ruth, Kennish, Steven, Morgan, Susan, Vigano, Selena, Romero, Pedro J, Evans, Thomas, Catto, James, Hamdy, Freddie, Hill, Adrian V S, Redchenko, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319775/
https://www.ncbi.nlm.nih.gov/pubmed/32591433
http://dx.doi.org/10.1136/jitc-2020-000928

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319775/
https://www.ncbi.nlm.nih.gov/pubmed/32591433
http://dx.doi.org/10.1136/jitc-2020-000928

Ejemplares similares